Tesofensine vs Tirzepatide

Tesofensine wins for: rapid onset of appetite suppression, high efficacy at lower body weights, major impact on food noise (especially in stimulant-resistant or GLP-1-tolerant cases), oral convenience, and as a targeted tool for cutting phases where stimulant side effects are tolerated and central drive is needed.

Tirzepatide wins for: sheer potency of weight loss, lean loss mitigation (when protocol is optimized), side effect profile that's manageable and predictable (mainly GI), major improvements in glucose control, long-term sustainability, and the unmatched capacity to reset body weight set-point over a full year plus cycle.

Pick Tesofensine if:

• Appetite suppression is the main goal and a near-immediate "off switch" for food noise is needed
• Previous GLP-1s (semaglutide, tirzepatide) have stalled or lost efficacy
• Oral dosing is preferred and cardiovascular risk is manageable
• Shorter, aggressive cutting phases are planned
• Sourcing or cost makes GLP-1s impractical or unreliable

Pick Tirzepatide if:

• Maximum sustainable fat loss is the top priority, especially in high-BMI protocols
• Preserving lean mass during longer cuts, recomp, or contest prep
• Appetite and glucose spikes need to be controlled with minimal cognitive or stimulant side effects
• Tolerating GI adaptation and slower onset is acceptable (2–6 weeks titration)
• Safety, long-term metabolic health, and minimal stimulant risk are prioritized